A E Athanasiou

Phase II study of liposomal cisplatin (Lipoplatin™) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer

N. Mylonakis, A E Athanasiou, Nikolaos Ziras et al. · Lung Cancer · 2009 · 96 citations

Liposomal Cisplatin, Medicine, Pathology +7

G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history

Theodore Anagnostopoulos, Maroulio Pertesi, Irene Konstantopoulou et al. · Breast Cancer Research and Treatment · 2007 · 43 citations

Breast Oncology, Somatic Variant, Medicine +7

Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases

Sophia Armaou, Maroulio Pertesi, Florentia Fostira et al. · British Journal of Cancer · 2009 · 36 citations · Full text

9088 Phase III study of Lipoplatin plus Gemcitabine versus Cisplatin plus Gemcitabine in advanced NSCLC; interim analysis

Christos Kosmas, J H Angel, A E Athanasiou et al. · European Journal of Cancer Supplements · 2009 · 18 citations

Advanced Nsclc, Interim Analysis, Biochemistry +4

Serious hematologic complications following erlotinib treatment.

George P. Stathopoulos, Dim Trafalis, A E Athanasiou et al. · PubMed · 2010 · 10 citations